Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies medrxivpreprint typetwodiabetes T2D diabetes type2 personalised personalizedmedicine
By Pooja Toshniwal PahariaAug 10 2023Reviewed by Lily Ramsey, LLM In a recent study posted to the medRxiv* preprint server, researchers developed a personalized therapy selection algorithm for two diabetes type 2 treatment drug classes, i.e., sodium-glucose cotransporter 2 -inhibitors and glucagon-like peptide-1 -receptor agonist medications.
Further research is required on the two classes of drugs to increase their generalizability and widen the therapeutic landscape of T2D. Specific cohorts were developed for secondary outcomes to maximize the number of patients included in each study. The researchers evaluated the impact of glycemic response-based targeted treatment on secondary outcomes like tolerability, weight change, long-term risks of adverse renal events, and incident microvascular and macrovascular problems.
Results The model detected 112,274 T2D patients who did not receive insulin therapy and started GLP1-receptor agonists or SGLT2 inhibitors in the United Kingdom from January 2013 to October 2020. The mean participant age was 58, 59% were male, and 79% were White. A 7.40 mmol/mol advantage for SGLT2i was reported among 4.0% of patients with a model-estimated glycemic advantage higher than 5.0 mmol/mol for SGLT2 inhibitors over GLP1-receptor agonists.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'Why not treat them as human beings?': Caller defends Diane Abbott's controversial migrant tweetThis furious caller supports Independent MP Diane Abbott's retaliation to Lee Anderson's controversial migrant comments.
Read more »
The number of steps required to burn off junk foods like pizza and pintsNew research has shown that one popular treat typically enjoyed late at night can take an eye-watering 11 hours to walk off.
Read more »
Wegovy weight loss drug also cuts risk of heart attack and stroke by 20 per cent, trial shows🔴 The Wegovy weight loss drug reduces the risk of heart attacks and strokes by a fifth for people with obesity, according to the results of a major trial
Read more »
Wegovy weight loss drug set for use on NHS also cuts heart attack and stroke risk, trial showsA weight-loss jab which could be available on the NHS by the end of the year can also reduce the risk of a heart attack or stroke by 20% Although it is not yet clear when the drug could be approved for such use in the UK PMGallagher1 and BawdenTom
Read more »
Can CBT help type 2 diabetes and obesity patients implement lifestyle alterations?Can CBT help type 2 diabetes and obesity patients implement lifestyle alterations? SciReports CBT diabetes obesity lifestyle health
Read more »
The immune-modulatory effect of lenvatinib investigated in new studyThe immune-modulatory effect of lenvatinib investigated in new study SciReports thyroidcancer oncology cancer disease health
Read more »